The beat, raised guidance, and increased buyback authorization signal strong operational execution and management confidence. Monitor for continued same-store discharge growth and margin expansion from new hospital openings in H2 2026; the raised revenue and EPS guidance sets a higher bar for Q3 and Q4.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 6 $124.82entry
- T+1 · 3mo ago +0.33%α −0.28% · $125.23
- T+5 · 3mo ago −1.50%α −2.71% · $122.95
- T+20 · 3mo ago −1.79%α −2.39% · $122.59
- T+60 · 18d ago +8.88%α +10.55% · $135.90
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Encompass Health reported Q2 2026 diluted EPS of $1.55, beating consensus of $1.48 by 4.7%, and net operating revenue of $1.597B, slightly above the $1.57B consensus. The company raised full-year 2026 guidance for revenue, adjusted EBITDA, and adjusted EPS, and expanded its stock repurchase authorization to $1 billion, reflecting confidence in continued strong operational performance.
Key Financial Metrics
Key Facts
- Q2 2026 diluted EPS from continuing operations $1.55 vs consensus $1.48 (beat by 4.7%)
- Net operating revenue $1,597.4M vs consensus $1,570M (beat by 1.7%)
- Revenue grew 9.6% YoY; Adjusted EBITDA grew 9.2% YoY to $348.0M
- Full-year 2026 guidance raised: revenue to $6,410-$6,490M, adjusted EPS to $6.02-$6.25
- Board increased stock repurchase authorization to $1 billion; $145.8M repurchased YTD
- Same-store discharge growth 2.8%; total discharges up 5.6% YoY
Financial Impact
EPS beat of $0.07 (4.7%) and revenue beat of $27.4M (1.7%) with raised full-year guidance midpoint for EPS by $0.13-0.14 and revenue by $35M at midpoint
Risk Factors
- Labor cost inflation and staffing shortages could pressure margins
- Medicare/Medicaid reimbursement changes or regulatory shifts
- Execution risk on planned hospital openings and bed additions
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-prn-302844091 |
Track record
14 reports on EHC
2 of 3 bullish or bearish reports moved the stock their way by T+1. Best: +7.44% at T+5 after the Oct 28, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 6, 202610d ago 8-K Neutral 4/10 Entry $137.54 to $141.15 Now $142.11 +3.32% ▲ +2.62% +0.26% vs SPY
- Oct 28, 202619d ago 8-K Bullish 6/10 No price data
- Oct 28, 202619d ago Press Release Bullish 6/10 Entry $131.49 to $135.90 Now $142.11 +8.08% ▲ +3.35% +5.13% vs SPY
- Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $122.09 to $131.49 Now $142.11 +16.40% ▲ +7.70% +8.08% vs SPY
- Oct 23, 202624d ago Institutional Cluster Neutral 2/10 Entry $124.09 to $124.10 Now $142.11 +14.52% ▲ +0.01% −0.70% vs SPY
- Oct 22, 202625d ago Press Release Neutral 2/10 Entry $126.01 to $124.09 Now $142.11 +12.78% ▼ −1.52% −1.00% vs SPY
- Oct 1, 20266w ago Press Release Neutral 1/10 Entry $119.80 to $120.97 Now $142.11 +18.62% ▲ +0.98% +0.30% vs SPY
- Sep 1, 202610w ago Insider Cluster Neutral 3/10 Entry $122.05 to $121.18 Now $142.11 +16.44% ▼ −0.71% −1.16% vs SPY
- Aug 11, 202613w ago Insider Cluster Bearish 5/10 Entry $125.35 to $124.83 Now $142.11 −13.37% ▲ +0.41% +0.67% vs SPY
- Aug 5, 202614w ago Press Release Bullish 7/10 Viewing Entry $124.82 to $125.23 Now $142.11 +13.85% ▲ +0.33% −0.28% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers